U.S. reviews multibillion-dollar flu campaign

The Obama administration is considering whether the country should launch a fall vaccine campaign that administers three jabs, one for seasonal flu and two more to guard against swine flu.

The multibillion-dollar effort would trigger the same concerns that the WHO has to consider. Any move to purchase a large quantity of swine flu vaccine would shift production from seasonal jabs to a special variety. That could create shortfalls of seasonal vaccine in the U.S. or in other countries. The U.S. would need 180 million doses of seasonal vaccine and 600 million doses of vaccine to guard against A/H1N1.

"They have never tried this before, and there is going to be a great deal of confusion," said William Schaffner, chairman of the Department of Preventive Medicine at Vanderbilt University School of Medicine.

HHS officials, meanwhile, say that the U.S. is on its way to creating a vaccine that will protect people from swine flu.

- read the report from the Washington Post

ALSO: Anthony Fauci, head of the NIH's National Institute of Allergy and Infections Diseases, says the group is already on its way to developing a vaccine. Seed viruses are being prepared as a crucial first-step toward manufacturing a new vaccine. Report

PLUS: Canadian scientists have completed the first full sequencing of the H1N1 strain, which should help make it easier to develop a vaccine. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.